On 21 June 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Longrange, intended for the treatment and prevention of parasitic infections in cattle.
The company that applied for authorisation is Merial. The company requested a re-examination of the initial opinion. After considering the grounds for this request, the CVMP re-examined the opinion and confirmed the refusal of the marketing authorisation on 11 October 2018.
Questions and answers on the refusal of the marketing authorisation for Longrange (PDF/71.17 KB)
First published: 21/03/2019
|International non-proprietary name (INN) or common name||